Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 4
4 · Metsera, Inc. · Filed Feb 3, 2025
Insider Transaction Report
Form 4
Metsera, Inc.MTSR
Transactions
- Conversion
Common Stock
2025-01-30+1,857,699→ 1,857,699 total - Conversion
Series B Preferred Stock
2025-01-30−4,365,079→ 0 total→ Common Stock (1,857,699 underlying)
Footnotes (1)
- [F1]Each share of Series B Preferred Stock automatically converted into Common Stock on a 2.349723-for-1 basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date.